Compare metabolites in 2 of these studies:
Study A:   Study B:  

List of Studies ( Metabolite:Lys-Pro-Pro)

Study_idAnalysis_idStudy_titleSourceSpeciesDiseaseInstituteAnalysis Type
ST003778 AN006205 Human to mouse microbiota transfer model demonstrates disease-modifying effects of the short-chain fatty acid biotherapy modified microbiota Feces Mouse Diabetes University of Queensland LC-MS
ST003565 AN005857 Metaboloomics analysis of the antimalarial compound WEHI-1888504 (aka compound 59) in Plasmodium falciparum (3D7) infected red blood cells Cultured cells Plasmodium falciparum Malaria Monash University LC-MS
ST003521 AN005782 Metabolic Profiling Unveils Enhanced Antibacterial Synergy of Polymyxin B and Teixobactin against Multi-Drug Resistant Acinetobacter baumannii Bacterial cells Acinetobacter baumannii Bacterial infection Monash University LC-MS
ST003179 AN005221 Property and Activity Refinement of Dihydroquinazolinone-3-carboxamides as Orally Efficacious Antimalarials that Target PfATP4 Plasmodium cells Plasmodium falciparum Malaria Monash University LC-MS
ST003036 AN004977 Identifying and mathematically modeling the time-course of extracellular metabolic markers associated with resistance to ceftolozane/tazobactam in Pseudomonas aeruginosa - Part 2 Bacterial cells Pseudomonas aeruginosa Bacterial infection Monash Institute of Pharmaceutical Sciences LC-MS
ST003036 AN004978 Identifying and mathematically modeling the time-course of extracellular metabolic markers associated with resistance to ceftolozane/tazobactam in Pseudomonas aeruginosa - Part 2 Bacterial cells Pseudomonas aeruginosa Bacterial infection Monash Institute of Pharmaceutical Sciences LC-MS
ST003024 AN004958 Identifying and mathematically modeling the time-course of extracellular metabolic markers associated with resistance to ceftolozane/tazobactam in Pseudomonas aeruginosa - Part 1 Bacterial cells Pseudomonas aeruginosa Monash Institute of Pharmaceutical Sciences LC-MS
  logo